CA2281955C - Kinase inhibitrice de nf-kb (ikb), sous-unites de la kinase ikb et procedes d'utilisation - Google Patents

Kinase inhibitrice de nf-kb (ikb), sous-unites de la kinase ikb et procedes d'utilisation Download PDF

Info

Publication number
CA2281955C
CA2281955C CA002281955A CA2281955A CA2281955C CA 2281955 C CA2281955 C CA 2281955C CA 002281955 A CA002281955 A CA 002281955A CA 2281955 A CA2281955 A CA 2281955A CA 2281955 C CA2281955 C CA 2281955C
Authority
CA
Canada
Prior art keywords
ikk
leu
ser
glu
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002281955A
Other languages
English (en)
Other versions
CA2281955A1 (fr
Inventor
Michael Karin
Joseph A. Didonato
David M. Rothwarf
Makio Hayakawa
Ebrahim Zandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/810,131 external-priority patent/US6268194B1/en
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2281955A1 publication Critical patent/CA2281955A1/fr
Application granted granted Critical
Publication of CA2281955C publication Critical patent/CA2281955C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1101—IkappaB kinase (2.7.11.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention concerne des molécules d'acides nucléiques isolées, codant des polypeptides de la sous-unité catalytique de la kinase I kappa B (IKK), qui sont associées à une protéine kinase sérine phosphorylant une protéine (I kappa B) qui inhibe l'activité du facteur de transcription NF- kappa B; des vecteurs contenant ces molécules d'acides nucléiques; et des cellules hôtes contenant ces vecteurs. En outre, l'invention concerne des séquences nucléotidiques qui peuvent se fixer sur une molécule d'acides nucléiques de l'invention, ces séquences nucléotidiques étant utilisées comme sondes ou comme molécules anti-sens. L'invention concerne également des sous-unités catalytiques isolées de l'IKK qui peuvent phosphoryler une protéine I kappa B et des parties peptidiques de cette sous-unité de l'IKK. En outre, l'invention traite d'anticorps anti-IKK, qui se fixent de manière spécifique à un complexe de l'IKK ou à une sous-unité catalytique de l'IKK, ainsi que des fragments se fixant sur l'IKK de ces anticorps. L'invention concerne par ailleurs des procédés de purification sensible d'un complexe de l'IKK, des procédés d'identification d'un agent qui peut modifier l'association d'un complexe de l'IKK, ou d'une sous-unité catalytique de l'IKK, avec une seconde protéine, et des procédés d'identification de protéines qui peuvent interagir avec un complexe de l'IKK ou une sous-unité catalytique de l'IKK.
CA002281955A 1997-02-25 1998-02-23 Kinase inhibitrice de nf-kb (ikb), sous-unites de la kinase ikb et procedes d'utilisation Expired - Lifetime CA2281955C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/810,131 1997-02-25
US08/810,131 US6268194B1 (en) 1997-02-25 1997-02-25 IKB kinase and methods of using same
US6147097P 1997-10-09 1997-10-09
US60/061,470 1997-10-09
PCT/US1998/003511 WO1998037228A1 (fr) 1997-02-25 1998-02-23 KINASE INHIBITRICE DE NF-λB (IλB), SOUS-UNITES DE LA KINASE IλB ET PROCEDES D'UTILISATION

Publications (2)

Publication Number Publication Date
CA2281955A1 CA2281955A1 (fr) 1998-08-27
CA2281955C true CA2281955C (fr) 2009-09-08

Family

ID=26741107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002281955A Expired - Lifetime CA2281955C (fr) 1997-02-25 1998-02-23 Kinase inhibitrice de nf-kb (ikb), sous-unites de la kinase ikb et procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP0981642A4 (fr)
JP (2) JP4125379B2 (fr)
AU (1) AU740622B2 (fr)
CA (1) CA2281955C (fr)
WO (1) WO1998037228A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728880T2 (de) 1996-03-19 2005-04-28 Millennium Pharmaceuticals, Inc., Cambridge KINASE FÜR DIE STELLEN-SPEZIFISCHE PHOSPHORYLIERUNG VON I-kappa-B-alpha
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6087169A (en) 1997-08-04 2000-07-11 Smithkline Beecham Plc HKABY60: polynucleotide encoding a helix-loop-helix ubiquitous kinase family polypeptide
EP0897009A3 (fr) * 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 polypeptides
US6030834A (en) * 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
JP2003526608A (ja) * 1998-10-15 2003-09-09 バイオイメージ エイ／エス 再分布及び／又は標的化での干渉によって得られる特異的治療の介入
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US5977341A (en) * 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
FR2787119A1 (fr) * 1998-12-09 2000-06-16 Inst Nat Sante Rech Med Procede de criblage en levure d'inhibiteurs de proteines kinases specifiques de cellules humaines et de mammiferes
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6468755B1 (en) 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity
KR101889140B1 (ko) * 2015-10-12 2018-08-17 연세대학교 산학협력단 p65의 전사 조절 도메인과 단백질 운반 도메인을 포함하는 신규 융합 단백질 및 이의 용도
CN115819603A (zh) * 2022-12-26 2023-03-21 广西大学 一种猪IKKα多克隆抗体的制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0920518A1 (fr) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Agent caracterise par un signal i(kappa)b kinase ikk] inductible par stimulus
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
EP0897009A3 (fr) * 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 polypeptides

Also Published As

Publication number Publication date
CA2281955A1 (fr) 1998-08-27
EP0981642A1 (fr) 2000-03-01
EP0981642A4 (fr) 2003-03-19
AU740622B2 (en) 2001-11-08
JP2001524813A (ja) 2001-12-04
JP4125379B2 (ja) 2008-07-30
JP2008115164A (ja) 2008-05-22
AU6664698A (en) 1998-09-09
WO1998037228A1 (fr) 1998-08-27

Similar Documents

Publication Publication Date Title
US20100055714A1 (en) IKB kinase, subunits thereof, and methods of using same
JP2008115164A (ja) ＩκＢキナーゼ、そのサブユニット、およびこれらを使用する方法
Michaud et al. 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3-and Ras-independent manner
CA2166981C (fr) Proteine kinase, carcinoproteine
JP3091769B2 (ja) プロテインキナーゼ
US6218136B1 (en) Methods of the identification of pharmaceutically active compounds
JP2008301815A (ja) 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム
CA2263835C (fr) Agent caracterise par un signal i(kappa)b kinase [ikk] inductible par stimulus
AU726294B2 (en) Ikk-alpha proteins, nucleic acids and methods
AU736316B2 (en) Mitogen-activated protein kinase p38-2 and methods of use therefor
US7902348B2 (en) Janus family kinases and identification of immune modulators
US7202049B2 (en) Mitogen-activated protein kinase p38-2 and methods of use therefor
AU758731B2 (en) Tao protein kinases and methods of use therefor
US6218515B1 (en) Cyclin E variants and use thereof
US6268194B1 (en) IKB kinase and methods of using same
CN100482795C (zh) Iren蛋白,其制备和应用
US20040097409A1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO1997003090A2 (fr) Kinase nucleaire localisee du facteur de transcription et dosages diagnostiques connexes
WO1994017180A1 (fr) Kinases situees dans le noyau, qui activent des facteurs de transcription

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180223